Swiss Red Cross

About: Swiss Red Cross is a nonprofit organization based out in Bern, Switzerland. It is known for research contribution in the topics: Population & Antibody. The organization has 407 authors who have published 420 publications receiving 10285 citations. The organization is also known as: Red Cross of Switzerland & Switzerland Red Cross.

Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity

Abstract: The glycosylation pattern of chCE7, an antineuroblastoma chimeric IgG1, was engineered in Chinese hamster ovary cells with tetracycline-regulated expression of beta(1,4)-N-acetylglucosaminyltransferase III (GnTIII), a glycosyltransferase catalyzing formation of bisected oligosaccharides that have been implicated in antibody-dependent cellular cytotoxicity (ADCC). Measurement of the ADCC activity of chCE7 produced at different tetracycline levels showed an optimal range of GnTIII expression for maximal chCE7 in vitro ADCC activity, and this activity correlated with the level of constant region-associated, bisected complex oligosaccharides determined by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. The new optimized variants of chCE7 exhibit substantial ADCC activity and, hence, may be useful for treatment of neuroblastoma. The strategy presented here should be applicable to optimize the ADCC activity of other therapeutic IgGs.

Large Scale Production of Human Plasma Fractions

Abstract: ummary The modifications put on the alcohol fractionation procedure of Nitschmann., Kistler and Lergier [8] since 1954 are communicated. The yields and purities realised were calculated from the results of about 150 fractionation runs, 100 1 of plasma each. The actual method allows the isolation of 48% of the total plasmaproteins as albumin (98% pure in electrophoretic analysis), 9,8% as γ-Globulin (practically 100% pure) and 3,4% as clottable fibrinogen. A scheme summarizes the details of the entire procedure. Resume Les modifications apportees depuis 1954 a la methode de fractionnement de Nitschmann, Kistler et Lergier [8] sont decrites. Le rendement et la purete des differents fractions ont ete calculees a partir des resultats de 150 fractionnements de 100 litres chacun. La methode actuelle permet d'obtenir 48% des proteines plasmatiques totales sous forme d'albumine (degre de purete electrophoretique de 98%), 9,8% sous forme de γ-globuline (degre de purete pratiquement de 100%) et 3,4% sous forme de fibrinogene coagulable. Un schema detaille risume l'ensemble du procede de fractionnement. Zusammenfassung: Die seit 1954 vorgenommenen Veranderungen der Alkoholfraktionierungsmethode nach Nitschmann, Kistler und Lergier [8] werden dargelegt. Die mit der Methode praktisch erzielten Ausbeuten und Reinheiten wurden aus den Ergebnissen von and 150 100-Liter-Plasma-Ansatzen ermittelt: Nnch dem heutigen Verfahren lassen sich etwa 48% der totalen Plasmaproteine als Albumin (ungefahr 98% elektrophoretisch rein), 9,80/, als γ-Globulin (praktisch 100prozentig rein) und 3,4% als gerinnbares Fibrinogen gewinnen. Das ganze Fraktionierverfahren ist in Form eines detaillierten Schemas zusammenfassend dargestellt.

Biodistribution, migration and homing of systemically applied mesenchymal stem/stromal cells

Abstract: Mesenchymal stem/stromal cells (MSCs) are increasingly used as an intravenously applied cellular therapeutic. They were found to be potent in situations such as tissue repair or severe inflammation. Still, data are lacking with regard to the biodistribution of MSCs, their cellular or molecular target structures, and the mechanisms by which MSCs reach these targets. This review discusses current hypotheses for how MSCs can reach tissue sites. Both preclinical and clinical studies using MSCs applied intravenously or intra-arterially are discussed in the context of our current understanding of how MSCs might work in physiological and pathological situations.